Appili Therapeutics Q1 2025 Earnings Report $0.03 0.00 (-8.36%) As of 01:53 PM Eastern Earnings History Appili Therapeutics EPS ResultsActual EPS-$0.01Consensus EPS -$0.01Beat/MissMet ExpectationsOne Year Ago EPSN/AAppili Therapeutics Revenue ResultsActual RevenueN/AExpected RevenueN/ABeat/MissN/AYoY Revenue GrowthN/AAppili Therapeutics Announcement DetailsQuarterQ1 2025Date8/13/2024TimeTASConference Call ResourcesAPLIF Earnings History Appili Therapeutics Earnings HeadlinesAppili Therapeutics Reports Financial and Operational Results for Third Quarter of Fiscal Year 2025February 14, 2025 | globenewswire.comAditxt to Host Fireside Chat on Friday, February 21st at 11:30 AM Eastern TimeFebruary 13, 2025 | businesswire.comNow that Trump’s be inaugurated, this day will be key (mark your calendar)Mark your calendar for March 13th. Because on that day, I believe we could see a $2 Trillion shock INTO the market… Unleashing more explosive moves than ever before.February 25, 2025 | Timothy Sykes (Ad)Appili Therapeutics Inc.: Appili Therapeutics Announces Receipt of Final Court Order for Arrangement with Aditxt, Inc.November 19, 2024 | finanznachrichten.deAppili Therapeutics Announces Receipt of Final Court Order for Arrangement with Aditxt, Inc.November 19, 2024 | globenewswire.comAppili Therapeutics Reports Financial and Operational Results for Second Quarter of Fiscal Year 2025November 14, 2024 | globenewswire.comSee More Appili Therapeutics Headlines Get Earnings Announcements in your inboxWant to stay updated on the latest earnings announcements and upcoming reports for companies like Appili Therapeutics? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Appili Therapeutics and other key companies, straight to your email. Email Address About Appili TherapeuticsAppili Therapeutics (OTCMKTS:APLIF), a biopharmaceutical company, focuses on the acquisition and development of novel medicines for unmet needs in infectious disease in Canada. Its anti-infective portfolio includes ATI-1501, a taste-masked liquid oral suspension formulation of the antibiotic metronidazole to treat anaerobic bacterial, protozoal, and parasitic infections; ATI-1801, a novel topical formulation of paromomycin in Phase III clinical trials for the treatment of cutaneous leishmaniasis and disfiguring skin infections; and ATI-1701, which is a live-attenuated vaccine in preclinical trials for Francisella tularensis. The company was incorporated in 2015 and is headquartered in Halifax, Canada.View Appili Therapeutics ProfileRead more More Earnings Resources from MarketBeat Earnings Tools Today's Earnings Tomorrow's Earnings Next Week's Earnings Upcoming Earnings Calls Earnings Newsletter Earnings Call Transcripts Earnings Beats & Misses Corporate Guidance Earnings Screener Earnings By Country U.S. Earnings Reports Canadian Earnings Reports U.K. Earnings Reports Latest Articles Price Targets on NVIDIA Rise in Front of EarningsThe Trade Desk Crashes on Earnings, But Growth Catalysts PersistHims & Hers Earnings Could Be a Game Changer—What to Do NowAnalysts See Buying Opportunity in NVIDIA Before EarningsAirbnb's Earnings: Sky High Results, Grounded Guidance?Is Coinbase Stock a Buy After Earnings?CVS Health: Earnings Beat Ignites Stock Rally Upcoming Earnings NVIDIA (2/26/2025)Synopsys (2/26/2025)Salesforce (2/26/2025)Lowe's Companies (2/26/2025)Snowflake (2/26/2025)TJX Companies (2/26/2025)Autodesk (2/27/2025)Canadian Imperial Bank of Commerce (2/27/2025)Dell Technologies (2/27/2025)Royal Bank of Canada (2/27/2025) Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.